Emmessar Biotech & Nutrition Ltd
NSE: BSE: 524768
₹25.91
(-3.64%)
Tue, 03 Mar 2026, 01:36 pm
Market Cap129.45M
PE Ratio38.87
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KEmmessar Biotech & Nutrition Analysis
dividend
- Unable to evaluate Emmessar Biotech & Nutrition's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Emmessar Biotech & Nutrition's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Emmessar Biotech & Nutrition is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
- Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
- Emmessar Biotech & Nutrition has no debt, it does not need to be covered by operating cash flow.
- Emmessar Biotech & Nutrition has no debt, it does not need to be covered by short term assets.
- Emmessar Biotech & Nutrition's cash and other short term assets cover its long term commitments.
- Emmessar Biotech & Nutrition currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Emmessar Biotech & Nutrition has no debt, therefore coverage of interest payments is not a concern.
- Emmessar Biotech & Nutrition has no debt.
- High level of physical assets or inventory.
management
- MSR's remuneration is lower than average for companies of similar size in India.
- MSR's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Emmessar Biotech & Nutrition is not covered by any analysts.
past
- Emmessar Biotech & Nutrition's 1-year earnings growth exceeds its 5-year average (48.7% vs 39.9%)
- Emmessar Biotech & Nutrition has delivered over 20% year on year earnings growth in the past 5 years.
- Emmessar Biotech & Nutrition used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Emmessar Biotech & Nutrition has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Emmessar Biotech & Nutrition has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Emmessar Biotech & Nutrition's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (48.7% vs 22.7%).
value
- Emmessar Biotech & Nutrition is good value based on assets compared to the IN Pharmaceuticals industry average.
- Emmessar Biotech & Nutrition is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Emmessar Biotech & Nutrition is good value based on earnings compared to the India market.
- BSE:524768 is up 6.3% along with the Pharmaceuticals industry (6.8%) over the past month.
- Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 524768 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524768 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524768 is up 6.3% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800